{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:04:09Z","timestamp":1789545849852,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,2,24]],"date-time":"2014-02-24T00:00:00Z","timestamp":1393200000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2014,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Current clinical assessments of motor function in Huntington\u2019s Disease (HD) rely on subjective ratings such as the Unified Huntington\u2019s Disease Rating scale (UHDRS). The ability to track disease progression using simple, objective, inexpensive, and robust measures would be beneficial.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>One objective measure of motor performance is hand-tapping. Over the last 14\u00a0years we have routinely collected, using a simple device, the number of taps made by the right and left hand over 30\u00a0seconds in HD patients attending our NHS clinics.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Here we report on a longitudinal cohort of 237 patients, which includes patients at all stages of the disease on a wide range of drug therapies. Hand tapping in these patients declines linearly at a rate of 5.1 taps per year (p\u2009&lt;\u20090.0001; 95% CI\u2009=\u20093.8 to 6.3 taps), and for each additional year of age patients could perform 0.9 fewer taps (main effect of age: p\u2009=\u20090.0007; 95% CI\u2009=\u20090.4 to 1.4). Individual trajectories can vary widely around this average rate of decline, and much of this variation could be attributed to CAG repeat length. Genotype information was available for a subset of 151 patients, and for each additional repeat, patients could perform 5.6 fewer taps (p\u2009&lt;\u20090.0001; 95% CI\u2009=\u20093.3 to 8.0 taps), and progressed at a faster rate of 0.45 fewer taps per year (CAG by time interaction: p\u2009=\u20090.008; 95% CI\u2009=\u20090.12 to 0.78 taps). In addition, for each unit decrease in Total Functional Capacity (TFC) within individuals, the number of taps decreased by 6.3 (95% CI\u2009=\u20095.4 to 7.1, p\u2009&lt;\u20090.0001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Hand tapping is a simple, robust, and reliable marker of disease progression. As such, this simple motor task could be a useful tool by which to assess disease progression as well therapies designed to slow it down.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2377-14-35","type":"journal-article","created":{"date-parts":[[2014,2,25]],"date-time":"2014-02-25T00:01:58Z","timestamp":1393286518000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A retrospective analysis of hand tapping as a longitudinal marker of disease progression in Huntington\u2019s disease"],"prefix":"10.1186","volume":"14","author":[{"given":"Lucy M","family":"Collins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley E","family":"Lazic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger A","family":"Barker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,2,24]]},"reference":[{"key":"962_CR1","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","volume":"72","author":"ME MacDonald","year":"1993","unstructured":"MacDonald ME, Ambrose CM, Duyao MP, Myers RH, Lin C, Srinidhi L, Barnes G, Taylor SA, James M, Groot N, MacFarlane H, Jenkins B, Anderson MA, Wexler NS, Gusella JF, Bates GP, Baxendale S, Hummerich H, Kirby S, North M, Youngman S, Mott R, Zehetner G, SEDLACEK Z, Poustka A, Frischauf AM, Lehrach H, Buckler AJ, Church D, Doucettestamm L, et al: A novel gene containing a trinucleotide repeat that is expanded and unstable on huntingtons-disease chromosomes. Cell. 1993, 72: 971-983. 10.1016\/0092-8674(93)90585-E.","journal-title":"Cell"},{"key":"962_CR2","doi-asserted-by":"publisher","first-page":"5733","DOI":"10.1073\/pnas.85.15.5733","volume":"85","author":"A Reiner","year":"1988","unstructured":"Reiner A, Albin RL, Anderson KD, D\u2019Amato CJ, Penney JB, Young AB: Differential loss of striatal projection neurons in huntington disease. Proc Natl Acad Sci U S A. 1988, 85: 5733-5737. 10.1073\/pnas.85.15.5733.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"962_CR3","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1212\/01.WNL.0000065888.88988.6E","volume":"60","author":"HD Rosas","year":"2003","unstructured":"Rosas HD, Koroshetz WJ, Chen YI, Skeuse C, Vangel M, Cudkowicz ME, Caplan K, Marek K, Seidman LJ, Makris N, Jenkins BG, Goldstein JM: Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology. 2003, 60: 1615-1620. 10.1212\/01.WNL.0000065888.88988.6E.","journal-title":"Neurology"},{"key":"962_CR4","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S1474-4422(09)70170-X","volume":"8","author":"SJ Tabrizi","year":"2009","unstructured":"Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RA, Durr A, Craufurd D, Kennard C, Hicks SL, Fox NC, Scahill RI, Borowsky B, Tobin AJ, Rosas HD, Johnson H, Reilmann R, Landwehrmeyer B, Stout JC, TRACK-HD Investigators: Biological and clinical manifestations of huntington\u2019s disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol. 2009, 8: 791-801. 10.1016\/S1474-4422(09)70170-X.","journal-title":"Lancet Neurol"},{"key":"962_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1474-4422(10)70276-3","volume":"10","author":"SJ Tabrizi","year":"2011","unstructured":"Tabrizi SJ, Scahill RI, Durr A, Roos RA, Leavitt BR, Jones R, Landwehrmeyer GB, Fox NC, Johnson H, Hicks SL, Kennard C, Craufurd D, Frost C, Langbehn DR, Reilmann R, Stout JC, TRACK-HD Investigators: Biological and clinical changes in premanifest and early stage huntington\u2019s disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol. 2011, 10: 31-42. 10.1016\/S1474-4422(10)70276-3.","journal-title":"Lancet Neurol"},{"key":"962_CR6","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1212\/WNL.57.5.920","volume":"57","author":"R Reilmann","year":"2001","unstructured":"Reilmann R, Kirsten F, Quinn L, Henningsen H, Marder K, Gordon AM: Objective assessment of progression in huntington\u2019s disease: a 3-year follow-up study. Neurology. 2001, 57: 920-924. 10.1212\/WNL.57.5.920.","journal-title":"Neurology"},{"key":"962_CR7","first-page":"1797","volume":"3","author":"C Beste","year":"2013","unstructured":"Beste C, Stock AK, Ness V, Hoffmann R, Lukas C: A novel cognitive-neurophysiological state biomarker in premanifest huntington\u2019s disease validated on longitudinal data. Sci Reports. 2013, 3: 1797-","journal-title":"Sci Reports"},{"key":"962_CR8","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1136\/jnnp-2011-301940","volume":"83","author":"JC Stout","year":"2012","unstructured":"Stout JC, Jones R, Labuschagne I, O\u2019Regan AM, Say MJ, Dumas EM, Queller S, Justo D, Santos RD, Coleman A, Hart EP, Durr A, Leavitt BR, Roos RA, Langbehn DR, Tabrizi SJ, Frost C: Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early huntington\u2019s disease. J Neurol Neurosurg Psychiatry. 2012, 83: 687-694. 10.1136\/jnnp-2011-301940.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"962_CR9","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S1474-4422(11)70263-0","volume":"11","author":"SJ Tabrizi","year":"2012","unstructured":"Tabrizi SJ, Reilmann R, Roos RAC, Durr A, Leavitt B, Owen G, Jones R, Johnson H, Craufurd D, Hicks SL, Kennard C, Landwehrmeyer B, Stout JC, Borowsky B, Scahill RI, Frost C, Langbehn DR, TRACK-HD Investigators: Potential endpoints for clinical trials in premanifest and early huntington\u2019s disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol. 2012, 11: 42-53. 10.1016\/S1474-4422(11)70263-0.","journal-title":"Lancet Neurol"},{"key":"962_CR10","first-page":"217","volume":"86","author":"E Clabough","year":"2013","unstructured":"Clabough E: Huntington\u2019s disease: the past, present, and future search for disease modifiers. Yale J Biol Med. 2013, 86: 217-233.","journal-title":"Yale J Biol Med"},{"key":"962_CR11","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/mds.870110204","volume":"11","author":"H Kremer","year":"1996","unstructured":"Kremer H: Unified huntington\u2019s disease rating scale: reliability and consistency. Mov Disord. 1996, 11: 136-142.","journal-title":"Mov Disord"},{"key":"962_CR12","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S1474-4422(11)70070-9","volume":"10","author":"DW Weir","year":"2011","unstructured":"Weir DW, Sturrock A, Leavitt BR: Development of biomarkers for huntington\u2019s disease. Lancet Neurol. 2011, 10: 573-590. 10.1016\/S1474-4422(11)70070-9.","journal-title":"Lancet Neurol"},{"key":"962_CR13","first-page":"379","volume":"81","author":"J Rupp","year":"2010","unstructured":"Rupp J, Blekher T, Jackson J, Beristain X: Progression in prediagnostic huntington disease. J Neurol. 2010, 81: 379-384.","journal-title":"J Neurol"},{"key":"962_CR14","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.neuropsychologia.2009.09.002","volume":"48","author":"JC Thompson","year":"2010","unstructured":"Thompson JC, Poliakoff E, Sollom AC, Howard E: Automaticity and attention in huntington\u2019s disease: when two hands are not better than one. Neuropsychologia. 2010, 48: 171-178. 10.1016\/j.neuropsychologia.2009.09.002.","journal-title":"Neuropsychologia"},{"key":"962_CR15","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1136\/jnnp.2007.128728","volume":"79","author":"JS Paulsen","year":"2008","unstructured":"Paulsen JS, Langbehn DR, Stout JC, Aylward E, Ross CA, Nance M, Guttman M, Johnson S, MacDonald M, Beglinger LJ, Duff K, Kayson E, Biglan K, Shoulson I, Oakes D, Hayden M, Predict-HD Investigators and Coordinators of the Huntington Study Group: Detection of huntington\u2019s disease decades before diagnosis: the predict-HD study. J Neurol Neurosurg Psychiatry. 2008, 79: 874-880. 10.1136\/jnnp.2007.128728.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"962_CR16","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S1474-4422(13)70088-7","volume":"12","author":"SJ Tabrizi","year":"2013","unstructured":"Tabrizi SJ, Scahill RI, Owen G, Durr A, Leavitt BR, Roos RA, Borowsky B, Landwehrmeyer B, Frost C, Johnson H, Craufurd D, Reilmann R, Stout JC, Langbehn DR, TRACK-HD Investigators: Predictors of phenotypic progression and disease onset in premanifest and early-stage huntington\u2019s disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol. 2013, 12: 637-649. 10.1016\/S1474-4422(13)70088-7.","journal-title":"Lancet Neurol"},{"key":"962_CR17","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1037\/a0018905","volume":"24","author":"KC Rowe","year":"2010","unstructured":"Rowe KC, Paulsen JS, Langbehn DR, Duff K: Self-paced timing detects and tracks change in prodromal huntington disease. Neuropsychology. 2010, 24: 435-442.","journal-title":"Neuropsychology"},{"key":"962_CR18","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s00415-008-0859-x","volume":"255","author":"AW Michell","year":"2008","unstructured":"Michell AW, Goodman AOG, Silva AHD, Lazic SE, Morton AJ, Barker RA: Hand tapping: a simple, reproducible, objective marker of motor dysfunction in huntington\u2019s disease. J Neurol. 2008, 255: 1145-1152. 10.1007\/s00415-008-0859-x.","journal-title":"J Neurol"},{"key":"962_CR19","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1212\/01.wnl.0000227890.87398.c1","volume":"67","author":"T Blekher","year":"2006","unstructured":"Blekher T, Johnson SA, Marshall J, White K, Hui S: Saccades in presymptomatic and early stages of huntington disease. Neurology. 2006, 67: 394-399. 10.1212\/01.wnl.0000227890.87398.c1.","journal-title":"Neurology"},{"key":"962_CR20","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1007\/s00415-010-5632-2","volume":"257","author":"CA Antoniades","year":"2010","unstructured":"Antoniades CA, Xu Z, Mason SL, Carpenter RHS, Barker RA: Huntington\u2019s disease: changes in saccades and hand-tapping over 3 years. J Neurol. 2010, 257: 1890-1898. 10.1007\/s00415-010-5632-2.","journal-title":"J Neurol"},{"key":"962_CR21","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.neulet.2007.02.027","volume":"416","author":"J Andrich","year":"2007","unstructured":"Andrich J, Saft C, Ostholt N, M\u00fcller T: Complex movement behaviour and progression of huntington\u2019s disease. Neurosci Lett. 2007, 416: 272-274. 10.1016\/j.neulet.2007.02.027.","journal-title":"Neurosci Lett"},{"key":"962_CR22","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1007\/s00415-003-0256-4","volume":"250","author":"C Saft","year":"2003","unstructured":"Saft C, Andrich J, Meisel NM, Przuntek H, M\u00fcller T: Assessment of complex movements reflects dysfunction in huntington\u2019s disease. J Neurol. 2003, 250: 1469-1474. 10.1007\/s00415-003-0256-4.","journal-title":"J Neurol"},{"key":"962_CR23","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3233\/NRE-130992","volume":"33","author":"T M\u00fcller","year":"2013","unstructured":"M\u00fcller T, Saft C, Andrich J, Harati A: Diadochokinetic movements differ between patients with huntington\u2019s disease and controls. NeuroRehabilitation. 2013, 33: 649-655.","journal-title":"NeuroRehabilitation"},{"key":"962_CR24","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1093\/hmg\/2.6.635","volume":"6","author":"YP Goldberg","year":"1993","unstructured":"Goldberg YP, Andrew SE, Clarke LA, Hayden MR: A PCR method for accurate assessment of trinucleotide repeat expansion in huntington disease. Hum Mol Genet. 1993, 6: 635-636.","journal-title":"Hum Mol Genet"},{"key":"962_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/WNL.29.1.1","volume":"29","author":"I Shoulson","year":"1979","unstructured":"Shoulson I, Fahn S: Huntington disease clinical care and evaluation. Neurology. 1979, 29: 1-3. 10.1212\/WNL.29.1.1.","journal-title":"Neurology"},{"key":"962_CR26","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1212\/WNL.31.10.1333","volume":"31","author":"I Shoulson","year":"1981","unstructured":"Shoulson I: Huntington disease: functional capacities in patients treated with neuroleptic and antidepressant drugs. Neurology. 1981, 31: 1333-1335. 10.1212\/WNL.31.10.1333.","journal-title":"Neurology"},{"key":"962_CR27","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1002\/mds.20939","volume":"21","author":"C Saft","year":"2006","unstructured":"Saft C, Andrich J, Meisel N-M, Przuntek H, M\u00fcller T: Assessment of simple movements reflects impairment in huntington\u2019s disease. Mov Disord. 2006, 21: 1208-1212. 10.1002\/mds.20939.","journal-title":"Mov Disord"},{"key":"962_CR28","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1136\/jnnp.2006.105338","volume":"78","author":"J Andrich","year":"2007","unstructured":"Andrich J, Saft C, Ostholt N, M\u00fcller T: Assessment of simple movements and progression of huntington\u2019s disease. J Neurol Neurosurg Psychiatry. 2007, 78: 405-407.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"962_CR29","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1080\/13803395.2011.574606","volume":"33","author":"DA Maroof","year":"2011","unstructured":"Maroof DA, Gross AL, Brandt J: Modeling longitudinal change in motor and cognitive processing speed in presymptomatic huntington\u2019s disease. J Clin Exp Neuropsychol. 2011, 33: 901-909. 10.1080\/13803395.2011.574606.","journal-title":"J Clin Exp Neuropsychol"},{"key":"962_CR30","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1001\/archneur.57.7.1040","volume":"57","author":"SC Kirkwood","year":"2000","unstructured":"Kirkwood SC, Siemers E, Bond C, Conneally PM, Christian JC, Foroud T: Confirmation of subtle motor changes among presymptomatic carriers of the huntington disease gene. Arch Neurol. 2000, 57: 1040-1044. 10.1001\/archneur.57.7.1040.","journal-title":"Arch Neurol"},{"key":"962_CR31","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/pst.532","volume":"10","author":"M Jenkins","year":"2011","unstructured":"Jenkins M, Flynn A, Smart T, Harbron C, Sabin T, Ratnayake J, Delmar P, Herath A, Jarvis P, Matcham J, PSI Biomarker Special Interest Group: A statistician\u2019s perspective on biomarkers in drug development. Pharm Stat. 2011, 10: 494-507. 10.1002\/pst.532.","journal-title":"Pharm Stat"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2377-14-35.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2377-14-35\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2377-14-35","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2377-14-35.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T03:06:40Z","timestamp":1630552000000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/1471-2377-14-35"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,24]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["962"],"URL":"https:\/\/doi.org\/10.1186\/1471-2377-14-35","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,24]]},"assertion":[{"value":"28 May 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"35"}}